Averitas Drug Patent Portfolio
Averitas owns 2 orange book drugs protected by 14 US patents Given below is the list of Averitas's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9012469 | Crystalline naloxol-peg conjugate | 02 Apr, 2032 | Active |
| US8821920 | Therapeutic patch for transdermal delivery of capsaicin | 26 Mar, 2030 | Active |
| US9226903 | Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer or the system and use of said back layer | 15 Dec, 2028 | Active |
| US7786133 | Chemically modified small molecules | 16 Sep, 2028 | Active |
| US10034841 | Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer | 06 Sep, 2025 | Expired |
| US8067431 | Chemically modified small molecules | 16 Dec, 2024 | Expired |
| US7056500 | Polymer conjugates of opioid antagonists | 29 Jun, 2024 | Expired |
| US10463598 | Compositions and kits for the removal of irritating compounds from bodily surfaces | 05 Sep, 2023 | Expired |
| US10869827 | Compositions and kits for the removal of irritating compounds from bodily surfaces | 05 Sep, 2023 | Expired |
| US8263059 | Compositions and kits for the removal of irritating compounds from bodily surfaces | 05 Sep, 2023 | Expired |
| US8889113 | Compositions and kits for the removal of irritating compounds from bodily surfaces | 05 Sep, 2023 | Expired |
| US7662365 | Polymer conjugates of opioid antagonists | 18 Oct, 2022 | Expired |
| US8617530 | Polymer conjugates of opioid antagonists | 18 Oct, 2022 | Expired |
| US6239180 | Transdermal therapeutic device and method with capsaicin and capsaicin analogs | 06 Nov, 2016 | Expired |
Latest Legal Activities on Averitas's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Averitas.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Maintenance Fee Reminder Mailed
Critical
| 29 Apr, 2024 | US8263059 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Jun, 2023 | US9226903 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Apr, 2023 | US10463598 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Sep, 2022 | US9012469 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 04 May, 2022 | US8889113 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 24 Feb, 2022 | US8821920 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 Jan, 2022 | US10034841 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 13 Jan, 2022 | US7786133 |
|
Patent Term Extension Certificate
Critical
| 06 Dec, 2021 | US7786133 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 Jul, 2021 | US7662365 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 May, 2021 | US8617530 |
| Mail Certificate of Correction Memo | 06 May, 2021 | US9012469 |
| Certificate of Correction Memo | 05 May, 2021 | US9012469 |
| Post Issue Communication - Certificate of Correction | 05 May, 2021 | US9012469 |
| Notice of Final Determination -Election Required | 16 Feb, 2021 | US7786133 |
Averitas's Drug Patent Litigations
Averitas's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 15, 2015, against patent number US7786133. The petitioner Neptune Generics, LLC, challenged the validity of this patent, with NEKTAR THERAPEUTICS as the respondent. Click below to track the latest information on how companies are challenging Averitas's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7786133 | October, 2015 |
Institution Denied
(27 Apr, 2016)
| NEKTAR THERAPEUTICS | Neptune Generics, LLC |
| US7786133 | October, 2015 |
Terminated-Denied
(27 Apr, 2016)
| NEKTAR THERAPEUTICS | Neptune Generics, LLC |
Averitas Drug Patents' Oppositions Filed in EPO
Averitas drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 22, 2014, by Generics (Uk) Ltd (Trading As Mylan). This opposition was filed on patent number EP04814802A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP11829686A | Sep, 2016 | ABG Patentes, S.L. | Patent maintained as amended |
| EP11829686A | Sep, 2016 | Stada-Arzneimittel Aktiengesellschaft | Patent maintained as amended |
| EP11829686A | Sep, 2016 | Generics [UK] Limited | Patent maintained as amended |
| EP04814802A | Oct, 2014 | Generics (UK) Ltd (trading as Mylan) | Opposition rejected |
Averitas's Family Patents
Averitas Drug List
Given below is the complete list of Averitas's drugs and the patents protecting them.
1. Movantik
Movantik is protected by 6 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9012469 | Crystalline naloxol-peg conjugate |
02 Apr, 2032
(6 years from now)
| Active |
| US7786133 | Chemically modified small molecules |
16 Sep, 2028
(2 years from now)
| Active |
| US8067431 | Chemically modified small molecules |
16 Dec, 2024
(10 months ago)
| Expired |
| US7056500 | Polymer conjugates of opioid antagonists |
29 Jun, 2024
(1 year, 3 months ago)
| Expired |
| US7662365 | Polymer conjugates of opioid antagonists |
18 Oct, 2022
(3 years ago)
| Expired |
| US8617530 | Polymer conjugates of opioid antagonists |
18 Oct, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Movantik's drug page
2. Qutenza
Qutenza is protected by 8 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8821920 | Therapeutic patch for transdermal delivery of capsaicin |
26 Mar, 2030
(4 years from now)
| Active |
| US9226903 | Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer or the system and use of said back layer |
15 Dec, 2028
(3 years from now)
| Active |
| US10034841 | Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer |
06 Sep, 2025
(a month ago)
| Expired |
| US10463598 | Compositions and kits for the removal of irritating compounds from bodily surfaces |
05 Sep, 2023
(2 years ago)
| Expired |
| US10869827 | Compositions and kits for the removal of irritating compounds from bodily surfaces |
05 Sep, 2023
(2 years ago)
| Expired |
| US8263059 | Compositions and kits for the removal of irritating compounds from bodily surfaces |
05 Sep, 2023
(2 years ago)
| Expired |
| US8889113 | Compositions and kits for the removal of irritating compounds from bodily surfaces |
05 Sep, 2023
(2 years ago)
| Expired |
| US6239180 | Transdermal therapeutic device and method with capsaicin and capsaicin analogs |
06 Nov, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qutenza's drug page